It is expected to reach $50 billion in revenue in ten years! A war against obesity is being waged
in the global pharmaceutical community.
It is reported that pharmaceutical companies such as Eli Lilly, Amgen, Pfizer, and Regeneron have targeted this broad track
.
For example, Eli Lilly has announced that the FDA has granted fast-track qualification for Tirzepatide (telpotide) injection for the treatment of obesity indications to accelerate the approval
of this indication.
As a GLP-1R/GIP dual-target hypoglycemic drug for the treatment of type 2 diabetes, this drug has attracted a lot of attention
in the experimental stage.
It is reported that according to the results of the phase 3 clinical trial SURPASS-2 published by Lilly, compared with Novo Nordisk 1 mg injectable semeglutide, three doses of Tirzepatide can significantly reduce
glycated hemoglobin and body weight from baseline in adult patients with type 2 diabetes.
The highest dose of Tirzepatide (15 mg) reduced glycosylated hemoglobin (A1C) by 2.
46% and body weight by 12.
4 kg (13.
1%); The lowest dose of Tirzepatide (5 mg) reduced A1C by 2.
09% and body weight by 7.
8 kg (8.
5%), compared with semeglutide by 1.
86% and 6.
2 kg (6.
7%)
, respectively.
In addition, according to the approval schedule, Mounjaro, a diabetes drug owned by Eli Lilly that has both hypoglycemic and weight reduction, is also expected to obtain indications
for the treatment of overweight next year.
On December 1, Amgen also announced the data
of its new phase 1 clinical trial of obesity therapy AMG 133.
According to public information, AMG 133 is a potential "first-in-class" antibody peptide conjugated drug, which is administered once a
month.
The results of the Phase 1 clinical trial showed that subjects lost 14.
5%
of their body weight after 12 weeks of treatment with the highest dose of AMG 133.
Amgen said AMG133 was designed based on preclinical and human genetic data, which suggest that GIPR inhibition is a weight loss strategy, especially when
combined with GLP-1 agonists.
"We look forward to launching the second phase of the study
early next year.
"
It is reported that Pfizer has also set its sights on this tens of billions of dollars market
.
In mid-December, the company announced that it would advance late-stage trials
of its oral GLP-1 drug.
At the investor conference, Pfizer envisioned the drug's potential
to reach $10 billion in annual sales by 2030.
From the perspective of the mode of administration, compared with injectable drugs, the affinity of oral drugs for patients is obviously much
better.
According to the data, glucagon-like peptide 1 (GLP-1) is a peptide hormone secreted by intestinal cells, which stimulates the secretion of insulin by binding to GLP-1 receptors and inhibits the secretion of glucagon, thereby promoting glucose metabolism
.
At the same time, it can also delay gastric emptying and suppress appetite
.
Therefore, it is a powerful target for the treatment of obesity and type 2 diabetes
.
In addition, Regeneron Pharmaceuticals is looking for breakthroughs from the perspective of gene therapy, the company found that a gene called GPR75 can reduce the probability of obesity in the population by 60%, and is currently working with multiple partners to develop different drug forms
.
Obesity is a chronic disease that requires long-term management
.
It is associated with
many serious health consequences and reduced life expectancy.
There are many obesity-related complications, including type 2 diabetes, heart disease, obstructive sleep apnea, nonalcoholic fatty liver disease, and cancer
.
At present, obesity has become one of the important factors affecting the health of residents, so it is urgent
to strengthen the research and development of related drugs.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
